Publications

2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006

2025

Nishida-Aoki, N, Zhu, S, Chan, M, Kang, Y, Fujita, M, Jiang, X, McCabe, M, Vaz, JM, Davidson, NE, Ghajar, CM, Hansen, K, Welm, A, Pillarisetty, VG and Gujral, TS. Drug screening in 3D microtumors reveals DDR1/2-MAPK12-GLI1 as a vulnerability in cancer-associated fibroblasts. Cell Reports Medicine. 2025.Sep 19:102357. Pubmed.

Chan, M, Zhu, Z, Nukaya, M, Ferreira, L, Ronnekleiv-Kelly, S, Riehle, KJ, Scott, JD, Yeung, RS and Gujral, TS. DNAJ-PKAc Fusion Heightens PLK1 Inhibitor Sensitivity in Fibrolamellar Carcinoma. Gut. 2025. 24 April 2025. doi: 10.1136/gutjnl-2024-334274. Pubmed.

Stepanov, I, Gottshall, NR, Ahmadianyazdi, A, Sinha, D, Lockhart, EJ, Nguyen, TN, Hassan, S, Horowitz, LF, Yeung, RS., Gujral, TS. and Folch, A. Low-Cost Robotic Manipulation of Live Microtissues for Cancer Drug Testing. Science Advances. 2025. 11,eads1631. Pubmed.

Gritti, I, Wan, J, Weeresekara, V, Vaz, JM, Tarantino, G, Holgersen, T, Vijay, BV, Kammula, AV, Kattel, P, Zhu, S, Vu, P, Chan, M, Wu, M, Gordan, JD, Patra, KC, Silveira, VS, Manguso, RT, Wein, MN, Ott, CJ, Qi, J, Liu, D, Sakamoto, K, Gujral, TS*, and Bardeesy, N*. DNAJB1-PRKACA fusion drives fibrolamellar liver cancer through impaired SIK signaling and CRTC2/p300-mediated transcriptional reprogramming. Cancer Discovery. 2025 Apr 2;15(4):862. Pubmed. * co-corresponding

Chan, M, Zhu, S, Russell, Z, Arora, S, Arakaki, A, Kumasaka, D, Szulzewsky, , Michealraj, A, Holland, EC and Gujral, TS. A Systems approach identifies MERTK as a therapeutic vulnerability in ZFTA-RELA-driven ependymomas. Preprint. 2025.05.14.636949

Paatela EM, St Amant FG, Hamm DC, Bennett SR, Gujral TS, van der Maarel SM, Tapscott SJ. A discrete region of the D4Z4 is sufficient to initiate epigenetic silencing. Hum Mol Genet. 2025 Jul 8:ddaf114.

Pang, Y, Li, Q, Sergi, Z, Yu, G, Kim, O, Lu, P, Chan, M, Sang, X, Wang, H, Ranjan, A, Robey, RW, Soheilian, F, Tran, B, Núñez, FJ, Zhang, M, Song, H, Zhang, W, Davis, D, Gilbert, MR, Gottesman, M, Liu, Z, Khan, J, Thomas, CJ, Castro, MG, Gujral, TS, and Wu, J. Exploiting the therapeutic vulnerability of IDH-mutant gliomas with zotiraciclib. iScience. 2025. 28(4):112283. Pubmed.

2024

Long, D, Chan, M, Han, M, Kamdar, Z, Ma, RK, Tsai, P, Francisco, AB, Barrow, J, Shackelford, DB, Yarchoan, M, McBride, MJ, Orre, LM, Vacanti, NM, Gujral, TS, and Sethupathy, P. Proteo-metabolomics and patient tumor slice experiments point to amino acid centrality for rewired mitochondria in fibrolamellar carcinoma. Cell Reports Medicine. 2024. Aug. 28101699. Pubmed.

Ho, C, Zhu, S, Gooley, T, Gujral, T.S, Lynch, RC, Poh, C, Shadman, M, Smith, SD, Tseng, Y and Gopal, AK. A phase 2 study of frontline pembrolizumab in follicular lymphoma. EJHaem. 2024 Oct 10;5(6):1173-118. Pubmed.

Nguyen, RN, Horowitz, L, Krilov, T, Lockhardt, E, Kenerson, H, Gujral, TS, Yeung, RS, Arroyo-Curras, N, Folch, A. Label-free, real-time monitoring of cytochrome C drug responses in microdissected tumor biopsies with a multi-well aptasensor platform. Science Advances. 10,eadn5875(2024). Pubmed.

Ma, RK, Tsai, P, Farghli, AR, Shumway, A, Kanke, M, Gordan, JD, Gujral, TS, Vakili, K, Nukaya, M, Noetzli, L, Ronnekleiv-Kelly, S, Broom, W, Barrow, J, Sethupathy, P. DNAJB1-PRKACA fusion protein-regulated LINC00473 promotes tumor growth and alters mitochondrial fitness in fibrolamellar carcinoma. PLoS Genetics. 2024. Mar 21;20(3):e1011216. Pubmed.

Lockhart, EJ, Horowitz, LF, Zhu, S, Nguyen, T, Mehrabi, M, Gujral, TS, and Folch, A. Drug testing of liver microdissected tumors using a multiwell microfluidic platform with valved hydodynamic traps. Lab on a Chip. 2024. In press. Pubmed.

2023

Chan, M#, Kang, Y#, Osborne, S, Zager, M and Gujral, TS. KinCytE- a Kinase to Cytokine Explorer to Identify Molecular Regulators and Potential Therapeutic Opportunities. eLife. 2023. 12:RP91472. Pubmed.

Olson, AT, Kang, Y, Ladha, AM, Zhu, S, Lim, CB, Nabet, B, Lagunoff, M, Gujral, TS*, and Geballe, AP*. Polypharmacology-based kinome screen identifies new regulators of KSHV reactivation. Plos Pathogens. 2023. 19(9), e1011169. Pubmed. *co-corresponding.

Poh C, Chow VA, Lynch RC, Ujjani CS, Shadman M, Till BG, Raghunathan V, Warren EH, Gauthier J, Smith SD, Gujral T, Morishima C, Wu Q, Voutsinas JM, Sperling A, Dzon J, Maloney DG, Gopal AK. Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis. Blood. 2023 Dec 1;142 (Supplement 1):2129

Huang, YL., Dickerson, LK., Kenerson, H, Jiang, X, Pillarisetty, V, Tian, Q, Hood, L, Gujral, TS* and Yeung, R.S., 2023. Organotypic Models for Functional Drug Testing of Human Cancers. BME frontiers, 4, p.0022. Pubmed. *co-corresponding.

Mossa, F, Robesti, D, Ramachandran, S, Corey, E, Titus, MA, Kang, Y, Zhang, J, Briganti, A, Montorsim F, Vellano, CP, Marszalek, JR, Frigo, DE, Logothetis, CJ, Gujral, TS, and Dondossola, E. Subtype and site specific-induced metabolic vulnerabilities in prostate cancer. Molecular Cancer Research. 2023. 21 (1): 51–61. Pubmed

2022

Szulzewsky, F Arora, S, Arakaki, A, Sievers, P, Bonin, D, Paddison, P, Sahm, F, Cimino, PJ, Gujral, TS, Holland, EC. 2022. Expression of YAP1-MAML2 and constitutively active YAP1 drive the formation of meningioma-like tumors in mice that resemble NF2-mutant meningiomas. Genes & Development. Pubmed.

Sullivan, KM, Jiang, X, Guha, P, Lausted, C, Carter, JA, Hsu, C, Labadie, KP, Kohli, K, Kenerson, HL, Daniel, SK, Yan, X, Meng,C, Chan, M, Abbasi, A, Seo, D, Park, JO, Crispe, N, Yeung, RS, Kim, TS, Gujral, TS, Tian, Q, Katz, sc, and Pillarisetty, VG. 2022. Blockade of interleukin-10 potentiates antitumor immune function in human colorectal cancer liver metastases. Gut. Pubmed.

Chan, M, Holland, E, and Gujral, TS. Olverembatinib inhibits SARS-CoV-2-Omicron variant-mediated cytokine release. EMBO molecular medicine. 2022. May 17. e15919. Pubmed

Kang, Y, Vijay, S, and Gujral, TS. Deep Neural Network Modeling Identifies Biomarkers of Response to Immune-checkpoint Therapy. iScience. 2022. 25 (5) May 20, 104228. Pubmed

Nishida-Aoki, N, and Gujral, TS. Polypharmacologic Reprogramming of Tumor-Associated Macrophages toward an Inflammatory Phenotype. Cancer Research. 2022. Feb 1. 13:canres.1428.202. Pubmed

2021

Bello T, Paindelli C, Diaz-Gomez LA, Melchiorri A , Mikos AG, Nelson PS, Dondossola E, and Gujral TS. Computational modeling identifies multi-targeted kinase inhibitors as effective therapies for castration-resistant prostate cancer. Proc Natl Acad Sci U S A. 2021. October 5, 118 (40) e2103623118. Pubmed.

Bello, T, Chan, M, Golkowski, M, Xue, AG, Khasnavis, N, Ceribelli, M, Ong,S, Thomas, C, and Gujral, TS. KiRNet: Kinase-centered network propagation of pharmacological screen results. Cell Reports Methods. 2021. 100007. Pubmed

Chan, M, Vijay, S., McNevin, J, McElrath, JM, Holland, EC, and Gujral, TS. Machine Learning Identifies Molecular Regulators and Inhibitors for COVID19-induced Cytokine Release. Molecular Systems Biology. 2021. Sep;17 (9):e10426. Pubmed

Arakaki, AKS, Szulzewsky, F, Gilbert, M, Gujral, TS, and Holland, EC. Utilizing Preclinical Models to Develop Targeted Therapies for Rare CNS Cancers. 2021. Neuro-Oncology. 23 (5) S4–S15. Pubmed

Arakaki, AKS., Pan, W, Wedegaertner, H, Roca-Mercado, I, Chinn, L, Gujral, TS, and Trejo, J. α-arrestin ARRDC3 tumor suppressor function is linked to GPCR-induced TAZ activation and breast cancer metastasis. Journal of Cell Science. 2021. Mar 15;jcs.254888. Pubmed

Horowitz, LF, Rodriguez, AD, Au-Yeung, A, Bishop, KW, Barner, LA, Mishra, G, Raman, A, Delgado, P, Liu, JTC, Gujral, TS, Mehrabi, M, Yang, M, Pierce, R, and Folch, A. Microdissected “cuboids” for microfluidic drug testing of intact tissues. Lab on a Chip. 2021. Jan 5;21(1):122-142. Pubmed.

2020

Golkowski, M, Lau, HT, Chan, M, Kenerson, H, Vidadala,VN, Shoemaker, A, Maly, DJ, Yeung, RS, Gujral, TS.*, and Ong, S*.Pharmacoproteomics identifies kinase pathways that drive the epithelial-mesenchymal transition and drug resistance in hepatocellular carcinoma. *Co-corresponding. Cell Systems. 2020. S2405-4712(20)30249-0. Pubmed

Szulzewsky, F, Arora, S, Hoellerbauer, P, King, C, Nathan, E, Chan, M., Cimino, P.J., Ozawa, T, Kawauchi, D, Pajtler, KW, Gilbertson, RJ, Paddison, PJ, Vasioukhin, V, Gujral, TS, and Holland, EC. Comparison of tumor-associated YAP1 fusions identifies a recurrent set of functions critical for oncogenesis. Genes & Development. 2020. 34: 1051-1064. Pubmed

Xue, A*, Chan, M*, and Gujral, TS. Pan-Cancer Analysis of the Developmental Pathways Reveals Non-canonocal Wnt signaling as a Driver of Mesenchymal-type Tumors. *Co-first. Translational Research. 2020. S1931-5244 (20 )30140-7. Featured New Investigator Article. Pubmed.

Siddharth, V, and  Gujral, TS.  Non-linear Deep Neural Network for Rapid and Accurate Prediction of Phenotypic Responses to Kinase Inhibitors. iScience. 2020. 23 (5). 101129. Pubmed.

Nishida-Aoki, N, Bondesson, AJ, and  Gujral, TS.  Measuring Real-time Drug Response in Organotypic Tumor Tissue Slices.  J. Vis. Exp. 2020. (159), e61036. Pubmed

Rata, S, Gruver, JS, Trikoz, N, Lukyanov, A, Vultaggio, J, Ceribelli, M, Thomas, C, Gujral, TS, Kirschner, MW, and Peshkin, L. An optimal set of inhibitors for Reverse Engineering via Kinase Regularization. 2020. bioRxiv.

2019

Sivakumar, R*., Chan, M*., Shin, J.S., Nishida-Aoki, N., Kenerson, H.L., Elemento, O., Beltran, H., Yeung, R and  Gujral, T.S. Organotypic tumor tissue slice cultures provide a versatile platform for immuno-oncology and drug discovery. *Co-first. OncoImmunology. 2019. 8(12): e1670019. Pubmed

Nishida-Aoki, N., and  Gujral. T.S. Emerging approaches to study cell-cell interactions in tumor microenvironment. Oncotarget. 2019. 10:785-797. Pubmed

2018

MacLeod, J., Gao, Y.,Hall, C.,Muller, W.J., Gujral, T.S  and Greer, P.A. Genetic disruption of calpain-1 and calpain-2 attenuates tumorigenesis in mouse models of HER2+ breast cancer and sensitizes cancer cells to doxorubicin and lapatinib. Oncotarget. 2018. 9:33382-33395. Pubmed.

Bello, T., and Gujral. T.S. KInhibition: A Kinase Inhibitor Selection Portal. iScience. 2018. 8, 49–53. Pubmed.

2017

Arang, N., Kain, H., Glennon, E., Bello, T., Dudgeon, D., Walter, E., Gujral, T.S. and Kaushansky, A. Identifying host regulators and inhibitors of liver stage malaria infection using kinase activity profiles. Nature Communications. 2017. 1;8(1):1232. Pubmed

Susman MW, Karuna EP, Kunz RC, Gujral TS, Cantú AV, Choi SS, Jong BY, Okada K, Scales MK, Hum J, Hu LS, Kirschner MW, Nishinakamura R, Yamada S, Laird DJ, Jao LE, Gygi SP, Greenberg ME, Ho HH. Kinesin superfamily protein Kif26b links Wnt5a-Ror signaling to the control of cell and tissue behaviors in vertebrates. Elife. 2017. 8;6. pii: e26509. Pubmed.

Gujral, T.S. and Kirschner M.W.  The Hippo pathway mediates resistance to cytotoxic drugs.  Proc Natl Acad Sci U S A. 2017. 114 (18) E3729-E3738. Pubmed

Pre-Gujral Lab Publications

2014

Gujral, T.S., Chan, M.,Peshkin, L., Sorger, P.K., Kirschner, M.W. and MacBeath, G. "A noncanonical Frizzled2 pathway regulates epithelial-mesenchymal transition and metastasis. " Cell. 2014. 159 (4), 844–856. Pubmed.

Gujral, T.S*., Peshkin, L*., and Kirschner M.W. "Exploiting polypharmacology for drug target deconvolution." Proc Natl Acad Sci U S A. 2014. 111 (13) 5048-5053. Pubmed.

2013

Gujral, T.S*., Karp, E.S*., Chan, M., Chang, B. and MacBeath, G. "Family-wide investigation of PDZ domain-mediated protein-protein interactions implicates β-catenin in maintaining the integrity of tight junctions. " Chemistry & Biology. 2013. 20, 816-27. Pubmed.

Hyndman, B.D*., Gujral, T.S*., Krieger, J.R., Cockburn, J.G. and Mulligan, L.M. "Multiple functional effects of RET kinase domain sequence variants in Hirschsprung disease." Human Mutation. 2013. 34, 132-42. Pubmed.

2012

Gujral, T.S., Karp., R, Finski,A., Chan, M., MacBeath, G and Sorger, P. "Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays." Oncogene. 2012. Pubmed.

Luckert, K*., Gujral, T.S.*, Chan, M., Joos, T.O., Sorger, P., MacBeath, G., and Potz, O. "A dual array-based approach to assess the abundance and posttranslational modification state of signaling proteins." Science Signaling. 2012. 5, pl1. Pubmed.

2011

Chang, B.H*., Gujral, T.S*.,  Karp, E.S., BuKhalid, R., Grantcharova, V.P., and MacBeath, G. "A systematic family-wide investigation reveals that ~30% of mammalian PDZ domains engage in PDZ-PDZ interactions." Chemistry & Biology . 2011. 18, 1143-52. Pubmed.

2010

Cockburn, J.G., Richardson, D.S., Gujral, T.S. & Mulligan, L.M.  "RET-mediated cell adhesion and migration require multiple integrin subunits." J Clin Endocrinol Metab. 2010. 95, E342-6. Pubmed.

Shalek, A.K., Robinson,  J.T., Karp, E., Seok Lee, J., Ahn, D., Yoon, M., Sutton, A.,  Jorgolli, M.,  Gertner, R., Gujral, T.S., MacBeath, G., Yang, E., and Park, H. "Vertical silicon nanowires as a universal platform for delivering biomolecules into living cells." Proc Natl Acad Sci U S A. 2010. 107, 1870-5. Pubmed.

Gujral, T.S. & Macbeath, G. "A system-wide investigation of the dynamics of Wnt signaling reveals novel phases of transcriptional regulation." PLoS One. 2010. 5, e10024. Pubmed.

2009

Richardson, D.S., Gujral, T.S., Peng, S., Asa, S.L. & Mulligan, L.M. "Transcript level modulates the inherent oncogenicity of RET/PTC oncoproteins." Cancer Research. 2009 69, 4861-9. Pubmed.

Gujral, T.S. & Macbeath, G. "Emerging miniaturized proteomic technologies to study cell signaling in clinical samples."  Science Signaling. 2009. 2, pe65.Pubmed.

2008

Gujral, T.S., Van Veelen, W., Richardson, D., Myers, S, Meens, J., Acton, D., Duñach, M, Elliott, B.E., and Mulligan, L. M. "A novel RET kinase-beta-catenin signaling pathway contributes to tumorigenesis in thyroid carcinoma. " Cancer Research. 2008. 68, 1338-46. Pubmed.

2007

Lai, A.Z., Gujral, T.S. & Mulligan, L.M. "RET signaling in endocrine tumors: delving deeper into molecular mechanisms."  Endocr Pathol. 2007. 18, 57-67. Pubmed.

2006

Gujral, T.S., Singh, V.K., Jia, Z. & Mulligan, L.M.  "Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2B." Cancer Research. 2006. 66, 10741-9. Pubmed.

Gujral, T.S. & Mulligan, L.M. "Molecular implications of RET mutations for pheochromocytoma risk in multiple endocrine neoplasia 2. " Ann N Y Acad Sci. 2006. 1073, 234-40. Pubmed.